Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OSE Immunotherapeutics SA (DE:6OP)
FRANKFURT:6OP
Holding DE:6OP?
Track your performance easily
6OP Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.15 - €10.68
Previous Close€8.84
Volume0.00
Average Volume (3M)506.00
Market Cap
€195.20M
Enterprise Value€199.78M
Total Cash (Recent Filing)€31.19M
Total Debt (Recent Filing)€35.77M
Price to Earnings (P/E)4.2
Beta0.75
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.09
Shares OutstandingN/A
10 Day Avg. Volume60
30 Day Avg. Volume506
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2.32
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.25Price Target Upside49.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
6OP FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest stock price was €3.15 and its highest was €10.68 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
Currently, no data Available
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Mar 27, 2025 which is in 121 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Sep 26, 2024. The company reported €2.628 earnings per share for the quarter, beating the consensus estimate of N/A by €2.628.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Undervalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 21,817,778 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of €2.628 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.067%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in DE:6OP
---
OSE Immunotherapeutics SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.72%
12-Months-Change
Fundamentals
Return on Equity
88.54%
Trailing 12-Months
Asset Growth
75.29%
Trailing 12-Months
Company Description
OSE Immunotherapeutics SA
Based in France, OSE Immunotherapeutics is a biotechnology company that creates and collaborates on treatments to regulate the immune system. It develops therapies for immuno-oncology (cancer) and immuno-inflammation (inflammatory diseases). The company’s current product portfolio includes Tedopi, Lusvertikimab (OSE-127), OSE-279, BI 770371, FR104/VEL-101, and ABBV-230. The company is led by CEO and Chief Scientific Officer, Nicolas Poirier.
---
6OP Stock 12 Month Forecast
Average Price Target
€13.25
▲(49.89% Upside)
Technical Analysis
Best Analysts Covering 6OP
1 Year
1 Year Success Rate
14/19 ratings generated profit
1 Year Average Return
+53.24%
reiterated a buy rating 8 days ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +53.24% per trade.
---